8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders

Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders

Hematologic malignancies represent clonal neoplastic proliferations of hematopoietic stem cells, myeloid precursors, or lymphoid elements. In the modern diagnostic laboratory, classifying these disorders requires an integrated approach synthesizing peripheral blood and bone marrow morphology, cytochemical staining, multiparametric flow cytometric immunophenotyping, cytogenetics (karyotyping and FISH), and next-generation molecular sequencing. MTLE licensure candidates must master diagnostic thresholds, cytochemical profiles, signature immunophenotypes, and molecular genetic drivers.

---

1. Diagnostic Frameworks: FAB vs WHO / ICC Guidelines

Over the past five decades, the classification of acute leukemias has evolved from purely morphologic descriptions to integrated genetic classifications:

                        ACUTE LEUKEMIA CLASSIFICATION CRITERIA

  ┌─────────────────────────────────────┐     ┌─────────────────────────────────────┐
  │   FAB CLASSIFICATION (1976)         │     │  WHO / ICC CLASSIFICATION (Current) │
  └──────────────────┬──────────────────┘     └──────────────────┬──────────────────┘
                     │                                           │
  • Blast Cutoff: ≥ 30% nucleated marrow cells. • Blast Cutoff: ≥ 20% in blood or marrow.
  • Diagnostic basis: Romanowsky morphology      • Diagnostic exceptions: Recurring genetic
    and cytochemical staining panel.               abnormalities (e.g., t(8;21), inv(16),
  • AML subdivided M0 through M7.                  t(15;17)) diagnosed as AML REGARDLESS
  • ALL subdivided L1, L2, L3.                     of blast percentage.
                                                 • Mandatory integration of flow cytometry,
                                                   cytogenetics, and molecular sequencing.

Clinical Presentation of Acute Leukemias

Acute leukemias are rapidly fatal if untreated, characterized by autonomous clonal blast proliferation that replaces normal hematopoietic tissue. The clinical presentation is defined by the triad of bone marrow failure:

1. Severe Anemia: Normocytic normochromic anemia causing severe fatigue, pallor, and tachycardia.
2. Profound Thrombocytopenia: Platelet counts often $<20 \times 10^9/\text{L}$, manifesting as petechiae, purpura, ecchymoses, epistaxis, and mucosal bleeding.
3. Severe Neutropenia: Despite marked leukocytosis (due to circulating blasts), absolute mature neutrophil counts are profoundly depressed, causing severe, recurrent bacterial and fungal infections.

---

2. Acute Myeloid Leukemia (AML) and Diagnostic Cytochemical Staining

Acute Myeloid Leukemia (AML) is characterized by clonal accumulation of myeloblasts, monoblasts, or megakaryoblasts in bone marrow and peripheral blood. A pathognomonic morphologic hallmark of myeloid lineage is the Auer rod—needle-shaped, azurophilic cytoplasmic inclusions formed by the abnormal crystallization and fusion of primary lysosomal granules rich in myeloperoxidase. Auer rods are never found in lymphoblasts.

                        CYTOCHEMICAL STAINING FLOWCHART

                               ┌─────────────────┐
                               │ LEUKEMIC BLASTS │
                               └────────┬────────┘
                                        │
                     ┌──────────────────┴──────────────────┐
                     ▼                                     ▼
              ┌──────────────┐                      ┌──────────────┐
              │   MPO / SBB  │                      │   MPO / SBB  │
              │   POSITIVE   │                      │   NEGATIVE   │
              └──────┬───────┘                      └──────┬───────┘
                     │                                     │
         ┌───────────┴───────────┐                 ┌───────┴───────┐
         ▼                       ▼                 ▼               ▼
  ┌──────────────┐        ┌──────────────┐  ┌──────────────┐┌──────────────┐
  │ CAE Positive │        │ NSE Positive │  │ PAS Block +  ││  PAS / TdT   │
  │ Granulocytic │        │ Monocytic    │  │ TdT Positive ││   Negative   │
  │ (AML M1-M3)  │        │ Inhibited by │  │ ALL (L1-L2)  ││ (AML M0/M7)  │
  └──────────────┘        │ Sodium Fluor.│  └──────────────┘└──────────────┘
                          │ (AML M4-M5)  │
                          └──────────────┘

Classical Cytochemical Staining Panel

Cytochemistry identifies cellular enzymatic activities and chemical constituents, establishing lineage identity when flow cytometry is unavailable:

1. Myeloperoxidase (MPO):
   • Principle: In the presence of hydrogen peroxide ($H_2O_2$), intracellular myeloperoxidase oxidizes an indicator chromogen (such as 3,3'-diaminobenzidine or 3-amino-9-ethylcarbazole), precipitating an insoluble dark brown-black or reddish-brown reaction product at sites of enzyme activity.
   • Reactivity: Localized within primary azurophilic granules of granulocytes. Positive in AML (FAB M1, M2, M3, M4); Negative in ALL.
2. Sudan Black B (SBB):
   • Principle: A lipophilic dye that partitions directly into intracellular neutral fats, phospholipids, and sterols present in primary and secondary granules.
   • Reactivity: Parallels MPO reactivity. Positive in granulocytic and myelomonocytic leukemias; negative in lymphoid leukemias. SBB is valuable because it can stain older, stored blood smears where enzymatic MPO has denatured.
3. Specific Esterase (Chloroacetate Esterase / CAE / Leder Stain):
   • Principle: Hydrolyzes naphthol AS-D chloroacetate, coupling with a diazonium salt to produce bright red cytoplasmic precipitation.
   • Reactivity: Specific for the granulocytic lineage (neutrophilic myeloblasts, promyelocytes, and mature neutrophils). Monocytes, lymphocytes, and erythroblasts are strictly negative.
4. Non-Specific Esterase (NSE / $\alpha$-Naphthyl Acetate or $\alpha$-Naphthyl Butyrate):
   • Principle: Hydrolyzes aliphatic esters. Demonstrates diffuse, intense reddish-brown cytoplasmic positivity in cells of the monocytic lineage (monoblasts, promonocytes, monocytes).
   • Sodium Fluoride (NaF) Inhibition Test: When an identical slide is pre-incubated with sodium fluoride, monocytic NSE activity is completely inhibited and abolished (fluoride-sensitive). In contrast, any trace esterase reactivity in granulocytes is fluoride-resistant. Essential for diagnosing FAB M4 (Acute Myelomonocytic Leukemia) and FAB M5 (Acute Monocytic Leukemia).
5. Periodic Acid-Schiff (PAS):
   • Principle: Periodic acid oxidizes glycols to dialdehydes, which react with Schiff's leucofuchsin to yield an intense magenta-pink color indicating intracellular glycogen.
   • Reactivity: Precursor B and T ALL blasts demonstrate a distinctive chunky, block-like, or coarse granular cytoplasmic positivity against a completely clear unstained background. Normal erythroid cells are PAS-negative; however, malignant erythroblasts in Acute Erythroleukemia (FAB M6) display coarse, intense PAS positivity.
6. Terminal Deoxynucleotidyl Transferase (TdT):
   • Principle: An intranuclear DNA polymerase that adds template-independent deoxynucleotides to 3'-OH ends during immunoglobulin and T-cell receptor gene rearrangement.
   • Reactivity: Positive in >95% of precursor B-ALL and T-ALL; negative in mature B-cell malignancies and mature lymphocytes. Negative in AML (except rare undifferentiated AML M0).

---

3. Acute Promyelocytic Leukemia (APL, FAB M3): Cytogenetics and Medical Emergency

Acute Promyelocytic Leukemia represents approximately 10% to 15% of AML cases and constitutes a life-threatening hematologic emergency requiring immediate recognition.

Morphology

• Bone marrow is heavily replaced by abnormal, large promyelocytes featuring heavy, coarse, hypergranular pink-purple cytoplasm, kidney-shaped or bilobed folded nuclei, and numerous stacked bundles of Auer rods within single cells, termed "faggot cells" (resembling a bundle of firewood).
• A microgranular (hypogranular) variant (APL M3v) also occurs, characterized by folded, bilobed "angel-wing" nuclei and submicroscopic granules.

Molecular Genetics

• Pathognomonic reciprocal balanced translocation $t(15;17)(q22;q21)$, fusing the Promyelocytic Leukemia ($PML$) gene on chromosome 15 to the Retinoic Acid Receptor Alpha ($RARA$) gene on chromosome 17.
• The resulting $PML\text{-}RARA$ fusion oncoprotein functions as a constitutive transcriptional repressor, binding chromatin and blocking retinoic-acid-dependent myeloid transcription, freezing granulocyte development at the promyelocyte stage.

Disseminated Intravascular Coagulation (DIC) Emergency

• Promyelocytic primary granules contain massive quantities of tissue factor, annexin II (a cell-surface tPA receptor that drives hyperfibrinolysis), and proteolytic enzymes.
• Granule release triggers catastrophic Disseminated Intravascular Coagulation (DIC) with systemic microvascular fibrin deposition, profound consumption coagulopathy (markedly prolonged PT/INR and aPTT), severe hypofibrinogenemia ($<100\text{ mg/dL}$), and surge in D-dimer. Patients frequently present with fatal intracranial or pulmonary hemorrhage.

Targeted Molecular Differentiation Therapy

• Unlike traditional cytotoxic chemotherapy (which induces cell lysis and exacerbates fatal DIC), APL is treated with pharmacologic doses of All-Trans Retinoic Acid (ATRA) combined with Arsenic Trioxide (ATO).
• ATRA directly binds the altered RARA ligand-binding domain, displacing co-repressors and inducing degradation of the $PML\text{-}RARA$ oncoprotein. This overcomes the maturation arrest, forcing the leukemic promyelocytes to terminally differentiate into non-dividing mature neutrophils, resolving the coagulopathy within 24 to 48 hours without cell lysis.

---

4. Acute Lymphoblastic Leukemia (ALL) and Immunophenotyping

ALL is the most common pediatric malignancy, accounting for 75% of childhood acute leukemias (peak incidence at 2 to 5 years of age).

FAB Morphologic Subtypes

• L1: Small, uniform blasts with high $N:C$ ratio, scant cytoplasm, round regular nuclei, and indistinct nucleoli (predominant pediatric type; 85% of cases; favorable prognosis).
• L2: Large, pleomorphic, heterogeneous blasts with lower $N:C$ ratio, irregular cleaved indented nuclei, and 1 to 2 prominent nucleoli (predominant adult ALL type; poor prognosis).
• L3 (Burkitt-Type ALL): Large, uniform blasts with round nuclei, dense chromatin, 1 to 3 nucleoli, and intensely basophilic cytoplasm containing prominent, lipid-filled vacuoles (staining with Oil Red O); displays $t(8;14)(q24;q32)$ fusing $MYC$ to the immunoglobulin heavy chain ($IGH$) locus.

Multiparametric Flow Cytometric Immunophenotyping

Flow cytometry using fluorochrome-conjugated monoclonal antibodies directed against Clusters of Differentiation (CD) antigens definitively establishes lymphoid lineage:

• Precursor B-Cell ALL (80-85% of cases):
  • Pan-B-cell markers: CD19, CD22, CD79a.
  • Immature progenitor markers: CD34, TdT, and CD10 (CALLA - Common ALL Antigen).
  • Maturation staging: Pro-B ALL (CD19+, CD10-), Common ALL (CD19+, CD10+), Pre-B ALL (cytoplasmic $\mu$ heavy chain positive), Mature B-ALL (surface immunoglobulin light chain restricted, CD10-).
• Precursor T-Cell ALL (15-20% of cases):
  • Pan-T-cell markers: CD2, CD3 (cytoplasmic and surface), CD5, CD7 (CD7 is the earliest T-cell marker; cytoplasmic CD3 is strictly T-lineage specific).
  • Dual positivity or negativity for CD4 and CD8, along with TdT+ and CD1a+.

---

5. Chronic Leukemias: CML and CLL

Chronic Myeloid Leukemia (CML)

• Pathogenesis: Myeloproliferative neoplasm originating in a pluripotent hematopoietic stem cell. Characterized by the reciprocal translocation $t(9;22)(q34.1;q11.2)$, creating the shortened chromosome 22 known as the Philadelphia chromosome ($Ph^1$).
• Molecular Mechanism: Fuses the $BCR$ gene on chromosome 22 to the $ABL1$ proto-oncogene on chromosome 9, producing the oncogenic BCR-ABL1 fusion transcript (usually $p210^{\text{BCR-ABL}}$). This encodes a constitutively active cytoplasmic protein tyrosine kinase that drives uncontrolled granulocytic proliferation and suppresses apoptosis.
• Natural Progression: Triphasic clinical course:
  1. Chronic Phase (3 to 5 years): Extreme leukocytosis ($50\text{--}500 \times 10^9/\text{L}$), complete granulocytic spectrum with prominent myelocytes, absolute basophilia, absolute eosinophilia, LAP score <20.
  2. Accelerated Phase: Rising peripheral/marrow blasts ($10\%\text{ to }19\%$ in the WHO 2016 criteria), worsening thrombocytopenia or thrombocytosis, persistent splenomegaly. The 2022 WHO 5th edition drops this phase in favor of high-risk chronic-phase features, while the ICC retains it.
  3. Blast Crisis: Acute leukemic transformation with $\ge 20\%$ blasts in blood or marrow (70% transform to AML, 30% to ALL).
• Targeted Therapy: Selective Tyrosine Kinase Inhibitors (TKIs: Imatinib, Dasatinib, Nilotinib) bind the ATP-binding pocket of BCR-ABL1, inducing complete cytogenetic and molecular remissions.

Chronic Lymphocytic Leukemia (CLL / SLL)

• Pathogenesis: The most common leukemia in older adults in Western nations (median age 70 years). Clonal accumulation of small, mature-appearing, immunologically incompetent B-lymphocytes.
• Diagnostic Requirement: Sustained monoclonal peripheral absolute lymphocytosis $\ge 5.0 \times 10^9/\text{L}$ ($5,000/\mu\text{L}$) persisting for at least 3 months.
• Peripheral Blood Smear:
  • Monomorphic sea of small, mature lymphocytes with dense, clumped, cracked "soccer-ball" or "turtle-shell" chromatin, scant cytoplasm, and absence of nucleoli.
  • Smudge Cells (Basket Cells): Numerous pale, pink-purple smeared artifacts produced by mechanical rupture of fragile leukemic lymphocytes during smear spreading.
  • Albumin Smear Preparation: To perform an accurate 100-cell differential, 1 drop of 22% bovine serum albumin (BSA) is mixed with 4 to 5 drops of anticoagulated blood prior to smear preparation. Albumin stabilizes the delicate cell membranes, eliminating smudge cells.
• Diagnostic Flow Cytometric Immunophenotype:
  • Co-expression of pan-B-cell markers (CD19, CD20 [dim], CD23) with the aberrant T-cell marker CD5.
  • Weak surface immunoglobulin (sIg) displaying monoclonal light chain restriction (pure $\kappa$ or pure $\lambda$ expression).
  • CD10 negative, Cyclin D1 negative (ruling out Mantle Cell Lymphoma).

---

6. Myeloproliferative Neoplasms (MPN) and Plasma Cell Dyscrasias

BCR-ABL1-Negative Myeloproliferative Neoplasms

Clonal stem cell disorders driven by somatic driver mutations producing autonomous, cytokine-independent trilineage marrow panmyelosis:

                      BCR-ABL1 NEGATIVE MPN OVERVIEW

  ┌───────────────────────┐  ┌───────────────────────┐  ┌───────────────────────┐
  │   POLYCYTHEMIA VERA   │  │ESSENTIAL THROMBOCYTHEM│  │ PRIMARY MYELOFIBROSIS │
  └───────────┬───────────┘  └───────────┬───────────┘  └───────────┬───────────┘
              │                          │                          │
              ▼                          ▼                          ▼
  • Autonomous erythrocytosis• Sustained platelets       • Progressive marrow
  • Hb >16.5 (M) / >16.0 (F)   > 450 x 10^9/L.             fibrosis (reticulin/coll)
  • Low serum EPO.           • Giant bizarre platelets.  • Colossal splenomegaly.
  • Splenomegaly, pruritus.  • Thrombosis & bleeding.    • Leukoerythroblastic
  • JAK2 V617F (>95%) or     • JAK2 (55%), CALR (25%),     smear + teardrop cells.
    JAK2 exon 12.              MPL (5%).                 • JAK2, CALR, or MPL.

1. Polycythemia Vera (PV):
   • Clonal panmyelosis dominated by autonomous erythrocyte overproduction independent of erythropoietin.
   • Criteria: Elevated Hemoglobin ($>16.5\text{ g/dL}$ in men; $>16.0\text{ g/dL}$ in women) or Hematocrit ($>49\%$ in men; $>48\%$ in women); hypercellular marrow with trilineage panmyelosis; and suppressed, subnormal serum EPO level.
   • Clinical Features: Hyperviscosity (headache, dizziness), vascular thrombosis, splenomegaly, and aquagenic pruritus (intense itching after warm baths due to basophil degranulation).
   • Genetics: $JAK2\text{ V617F}$ point mutation in exon 14 present in $>95\%$ of cases; remaining cases harbor mutations in $JAK2$ exon 12. The V617F substitution lies in the JH2 pseudokinase domain and disrupts its autoinhibitory control of the kinase domain, resulting in constitutive tyrosine kinase signaling.
2. Essential Thrombocythemia (ET):
   • Clonal proliferation dominated by the megakaryocytic lineage producing sustained extreme thrombocytosis (platelet count $>450 \times 10^9/\text{L}$, frequently $>1,000 \times 10^9/\text{L}$).
   • Smear exhibits giant bizarre platelets, megakaryocyte fragments, and platelet aggregates. Paradoxical bleeding (due to acquired von Willebrand syndrome from platelet consumption of large vWF multimers) and microvascular thrombosis (erythromelalgia).
   • Driven by mutations in $JAK2\text{ V617F}$ ($55\%$), Calreticulin ($CALR$, $25\%$), or Thrombopoietin receptor ($MPL$, $5\%$).
3. Primary Myelofibrosis (PMF):
   • Clonal proliferation of atypical megakaryocytes that release massive fibrogenic cytokines (TGF-$\beta$, PDGF, bFGF) into the marrow stroma, stimulating non-clonal fibroblasts to deposit dense reticulin and collagen fibers.
   • As fibrous tissue obliterates the marrow cavity, hematopoiesis relocates to the spleen and liver (extramedullary hematopoiesis), resulting in colossal splenomegaly.
   • Peripheral Smear Hallmark: Classic leukoerythroblastic reaction featuring teardrop erythrocytes (dacrocytes), nucleated red blood cells, immature granulocytes (myelocytes, metamyelocytes), and giant platelets.

Plasma Cell Dyscrasias: Multiple Myeloma (MM)

• Pathophysiology: Clonal neoplastic proliferation of terminally differentiated plasma cells in bone marrow secreting a monoclonal immunoglobulin (M-protein).
• Clinical CRAB Criteria:
  • C (Hypercalcemia): Serum calcium $>11.0\text{ mg/dL}$ due to plasma cell secretion of osteoclast-activating factors (RANKL, MIP-1$\alpha$).
  • R (Renal Failure): Serum creatinine $>2.0\text{ mg/dL}$; "myeloma kidney" caused by precipitation of toxic monoclonal light chains forming obstructive casts in distal tubules (cast nephropathy).
  • A (Anemia): Normocytic normochromic anemia due to bone marrow replacement.
  • B (Bone Lytic Lesions): Punched-out osteolytic bone lesions on skeletal survey, pathologic fractures, and severe bone pain.
• Laboratory Findings:
  • Peripheral Smear: Striking rouleaux formation ("stacks of coins"), where excessive circulating cationic paraproteins neutralize the negative zeta potential of red cells, promoting agglutination-like stacking. Occasional circulating plasma cells.
  • Serum Protein Electrophoresis (SPEP): Tall, narrow, monoclonal spike (M-spike) in the gamma or beta globulin region, most commonly IgG ($60\%$) or IgA ($25\%$).
  • Urine Studies: Bence Jones Proteinuria consisting of free monoclonal $\kappa$ or $\lambda$ light chains that filter through the glomerulus. Bence Jones proteins classically precipitate upon heating to $56^\circ\text{C}$ and redissolve upon boiling to $100^\circ\text{C}$.
  • Bone Marrow: $\ge 10\%$ (frequently $30\%\text{ to }90\%$) clonal plasma cells (featuring eccentric cartwheel nuclei, basophilic cytoplasm, and occasional Russell bodies [Mott cells] or flaming cytoplasm).